Share
Preview
Investments on Propel(x) are high risk, illiquid and bear the risk of partial or complete loss of invested capital. Please review risk factors for investments on Propel(x) here.
                                     
           6 April, 2021                                  
Propel(x) Insights
Are you a startup founder looking to raise money from angels? Our co-founder, Swati Chaturvedi shares her insights on 'How to fund raise from angel investors?'
         What influences your investing decisions the most? Let us know your thoughts.
    Deep technology companies are different from your average internet startup. Their risks are different, development timeline is different and cash needs are very different.

    Here's our framework which we use internally at Propel(x) to conduct diligence on deep technology startups.

    Starting at a high level – our goal is to identify companies that could yield favorable outcomes for investors; companies that potentially maximize sustained profitability.
    Public Opinion

    Propel(x) <> Deep Tech Poll

     
    Propel(x) covers six sectors within deep technology. If you were investing, which one would you invest in today?    
     
     
     
     
     
    Note: We are continuing this poll from our last newsletter to see if we can get more responses. Responses for this poll are being stored in Propel(x)'s Google Form.

    You can see what responses, others have submitted. We'll share the results in the next newsletter. Please encourage your friends to participate too!

    Share on Twitter

      Propel(x) D&I Insights
      Source : Internal Propel(x) Data | Pitchbook (US VC Female Founders Dashboard)
      Alumni Spotlight
      Aegis Life is a Bay Area-based preclinical biotech company that takes a novel approach to accelerate vaccine development. Currently, Aegis is working on bringing a pan-corona vaccine and therapeutics to market within 12 months.

      Aegis is a Propel(x) alumni company and closed on the platform in March 2021.

      Repurpose makes plant-based compostable products as an alternative to disposable plasticware. Ranked more than once as one of Inc 500’s fastest growing private companies, Repurpose is a Propel(x) alumni company which closed on the platform in July 2020.
      Mesentech is a Vancouver-based preclinical biotech company, developing novel drugs for treating bone disease. Mesentech’s technology was invented by Dr. Robert Young, a 30-year veteran of Merck, where he discovered Singulair®, Vioxx®, Arcoxia®, and Previcox®, among others.

      Mesentech is a Propel(x) alumni company and closed on the platform in June 2020.

      DEEP TECHNOLOGY BUZZ

      Disclosure
      - This section is for informational purposes only. It is not a solicitation to buy or sell a security.

      Here is what caught our attention over the past two weeks.
      Twitter Conversations
      Is AI > VC

      Gartner is using research done by  Harvard and MIT to conclude that algorithms trained on publicly available data can outperform early stage investors up to 184% in real world settings!

      Join the conversation on Twitter
      We are reading

      Propel(x) is a premier digital platform facilitating private venture capital for deep technology startups. Our mission is to enable investment in technologies that matter and thus build the next generation of great companies.

      Investors | Founders
      Investments on Propel(x) are high risk, illiquid and bear the risk of partial or complete loss of invested capital. Please review risk factors for investments on Propel(x) here.
       
       
       


      Email Marketing by ActiveCampaign